β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: A 3-year follow-up

European Journal of Endocrinology

Volumn 164, Issue 2, 2011, Pages 239-245

  Thunander, Maria ^a,b   Thorgeirsson, Hlin ^a   Törn, Carina ^c   Petersson, Christer ^d,e   Landin Olsson, Mona ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d Primary Care ^*  (Sweden)

^e R and D County Council   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN; METFORMIN; PANCREAS ISLET CELL ANTIBODY; SULFONYLUREA; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; BODY MASS; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET THERAPY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENCE; LATENT AUTOIMMUNE DIABETES; MALE; METABOLIC REGULATION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; DIABETIC DIET; DRUG SAFETY; EVENING DOSAGE; HUMAN CELL; INSULIN TREATMENT; LATENT AUTOIMMUNE DIABETES IN ADULTS; MULTICENTER STUDY; PANCREAS ISLET CELL FUNCTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; WEIGHT CHANGE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SWEDEN; TREATMENT OUTCOME;

EID: 78751504955     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0901     Document Type: Article

References (39)

1. Landin-Olsson M, Nilsson KO, Lernmark A & Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990 33 561-568. (doi:10.1007/BF00404145)
2. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay I, Shattock M, Bottazzo G & Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 1997 350 1288-1293. (doi:10.1016/S0140-6736(97)03062-6)
3. Landin-Olsson M. Latent autoimmune diabetes in adults. Annals of the New York Academy of Sciences 2002 958 112-116. (doi:10.1111/j.1749-6632.2002. tb02953.x)
4. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG & Harrison LC. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005 48 2206-2212. (doi:10.1007/s00125-005-1960-7)
5. Brophy S, Brunt H, Davies H, Mannan S & Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database of Systematic Reviews, 2007 CD006165. (doi:10.1002/14651858.CD006165.pub2)
6. Cernea S, Buzzetti R & Pozzilli P. Beta-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 2009 32 (Supplement 2) S246-S252. (doi:10.2337/dc09-S317)
7. Naik RG, Brooks-Worrell BM & Palmer JP. Latent autoimmune diabetes in adults. Journal of Clinical Endocrinology and Metabolism 2009 94 4635-4644. (doi:10.1210/jc.2009-1120)
8. Tsai EB, Sherry NA, Palmer JP & Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006 49 261-270. (doi:10.1007/s00125-005-0100-8)
9. Seissler J. Latent (slowly progressing) autoimmune diabetes in adults. Current Diabetes Reports 2008 8 94-100. (doi:10.1007/s11892-008-0018-x)
10. Krolewski AS, Warram JH, Rand LI & Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. New England Journal of Medicine 1987 317 1390-1398. (doi:10.1056/NEJM198711263172206)
11. Thunander M, Petersson C, Jonzon K, Fornander J, Ossiansson B, Torn C, Edvardsson S & Landin-Olsson M. Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Research and Clinical Practice 2008 82 247-255. (doi:10.1016/j.diabres.2008.07.022)
12. Neu A, Hofer SE, Karges B, Oeverink R, Rosenbauer J & Holl RW. Ketoacidosis at diabetes onset is still frequent in children and adolescents: a multicenter analysis of 14,664 patients from 106 institutions. Diabetes Care 2009 32 1647-1648. (doi:10.2337/dc09-0553)
13. Stenstrom G, Gottsater A, Bakhtadze E, Berger B & Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes 2005 54 (Supplement 2) S68-S72. (doi:10.2337/diabetes.54. suppl-2.S68)
14. Scholin A, Berne C, Schvarcz E, Karlsson FA & Bjork E. Factors predicting clinical remission in adult patients with type 1 diabetes. Journal of Internal Medicine 1999 245 155-162. (doi:10.1046/j.1365-2796.1999.00426.x)
15. Atkinson MA. Thirty years of investigating the autoimmune basis for type 1 diabetes. Diabetes 2005 54 1253-1263. (doi:10.2337/diabetes.54.5.1253)
16. Chaillous L, Bouhanick B, Kerlan V, Mathieu E, Lecomte P, Ducluzeau PH, Delamaire M, Sonnet E, Maugendre D, Marechaud R, Rohmer V, Sai P & Charbonnel B. Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control. Diabetes and Metabolism 2010 36 64-70. (doi:10.1016/j.diabet.2009.07.004)
17. Gotfredsen CF, Buschard K & Frandsen EK. Reduction of diabetes incidence of BBWistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985 28 933-935. (doi:10.1007/BF00703140)
18. Atkinson MA, Maclaren NK & Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990 39 933-937. (doi:10.2337/diabetes.39.8.933)
19. Kobayashi T, Nakanishi K, Murase T & Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996 45 622-626. (doi:10.2337/diabetes.45.5.622)
20. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS & Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004 53 250-264. (doi:10.2337/diabetes.53.1.250)
21. Steffes MW, Sibley S, Jackson M & Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003 26 832-836. (doi:10.2337/diacare.26.3. 832)
22. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P & Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine 2005 353 2643-2653. (doi:10.1056/NEJMoa052187)
23. Nordwall MA, Arnqvist HJ, Bojestig M & Ludvigsson J. Good glycemic control remains crucial in prevention of late diabetic complications - the Linkoping Diabetes Complications Study. Pediatric Diabetes 2008 10 168-176. (doi:10.1111/j.1399-5448.2008.00472.x)
24. Picardi A & Pozzilli P. Dynamic tests in the clinical management of diabetes. Journal of Endocrinological Investigation 2003 26 99-106.
25. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ & Eisenbarth GS. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998 47 1857-1866. (doi:10.2337/diabetes.47.12.1857)
26. Bingley PJ, Bonifacio E & Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003 52 1128-1136. (doi:10.2337/diabetes.52.5.1128)
27. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M & Wiedmeyer HM. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a methodcomparison study. Clinical Chemistry 2004 50 166-174. (doi:10.1373/clinchem.2003.024802)
28. Maruyama T, Tanaka S, Shimada A, Funae O, Kasuga A, Kanatsuka A, Takei I, Yamada S, Harii N, Shimura H & Kobayashi T. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2008 93 2115-2121. (doi:10.1210/jc.2007-2267)
29. Yang Z, Zhou Z, Li X, Huang G & Lin J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Research and Clinical Practice 2009 83 54-60. (doi:10.1016/j.diabres.2008.09.044)
30. Radtke MA, Midthjell K, Nilsen TI & Grill V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trondelag Health (HUNT) study. Diabetes Care 2009 32 245-250. (doi:10.2337/dc08-1468)
31. Desai M, Cull CA, Horton VA, Christie MR, Bonifacio E, Lampasona V, Bingley PJ, Levy JC, Mackay IR, Zimmet P, Holman RR & Clark A. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 2007 50 2052-2060. (doi:10.1007/s00125-007-0745-6)
32. Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA & Seissler J. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 2001 44 1005-1010. (doi:10.1007/s001250100602)
33. Jensen RA, Gilliam LK, Torn C, Landin-Olsson M, Karlsson FA, Palmer JP, Kockum I, Akesson K, Lernmark B, Lynch K, Breslow N & Lernmark A. Multiple factors affect the loss of measurable C-peptide over 6 years in newly diagnosed 15- to 35-year-old diabetic subjects. Journal of Diabetes and its Complications 2007 21 205-213. (doi:10.1016/j.jdiacomp.2006.01.004)
34. Borg H, Gottsater A, Fernlund P & Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adultonset diabetes. Diabetes 2002 51 1754-1762. (doi:10.2337/diabetes.51.6.1754)
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 837-853. (doi:10.1016/S0140-6736(98)07019-6)
36. Davis TM, Wright AD, Mehta ZM, Cull CA, Stratton IM, Bottazzo GF, Bosi E, Mackay IR & Holman RR. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005 48 695-702. (doi:10.1007/s00125-005-1690-x)
37. Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X & Zhou Z. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes/Metabolism Research and Reviews 2009 25 411-416. (doi:10.1002/dmrr.977)
38. Akirav E, Kushner JA & Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes 2008 57 2883-2888. (doi:10.2337/db07-1817)
39. Schatz D, Cuthbertson D, Atkinson M, Salzler MC, Winter W, Muir A, Silverstein J, Cook R, Maclaren N, She JX, Greenbaum C & Krischer J. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus - a new surrogate measure of non-progression? Pediatric Diabetes 2004 5 72-79. (doi:10.1111/j.1399-543X.2004.00047.x)